TCR2 Therapeutics Inc - ESG Rating & Company Profile powered by AI
This Sustainability score for TCR2 Therapeutics Inc represents the company's transparency towards the UN SDGs. The webpage is a zero-cost Environmental, Social and Governance report covering TCR2 Therapeutics Inc. Alternative corporations in the rating peer group for TCR2 Therapeutics Inc are displayed below.
TCR2 Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1967 | Hospira Inc | 0.3 | Low |
| 1967 | PRA Health Sciences Inc | 0.3 | Low |
| 1970 | TCR2 Therapeutics Inc | 0.0 | Low |
| 1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
| 1970 | CTC Bio Inc | 0.0 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does TCR2 Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes TCR2 Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes TCR2 Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes TCR2 Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes TCR2 Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes TCR2 Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes TCR2 Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes TCR2 Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes TCR2 Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes TCR2 Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes TCR2 Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes TCR2 Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes TCR2 Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes TCR2 Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes TCR2 Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes TCR2 Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes TCR2 Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid TCR2 Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes TCR2 Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes TCR2 Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas TCR2 Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes TCR2 Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes TCR2 Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes TCR2 Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes TCR2 Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes TCR2 Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes TCR2 Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes TCR2 Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs TCR2 Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes TCR2 Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes TCR2 Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes TCR2 Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes TCR2 Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes TCR2 Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes TCR2 Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes TCR2 Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for TCR2 Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.